<DOC>
	<DOCNO>NCT02623920</DOCNO>
	<brief_summary>This phase II trial study well brentuximab vedotin , bendamustine , rituximab work treat patient B-cell non-Hodgkin lymphoma return period improvement respond previous treatment . Monoclonal antibody-drug conjugate , brentuximab vedotin , use antibody target chemotherapy cancer cell . Drugs use chemotherapy , bendamustine , work different way kill cancer cell . Monoclonal antibody , rituximab , kill cancer cell directly , also harness immune system kill cancer cell . Adding brentuximab rituximab may improve response rate CD30 positive , CD20 positive Relapsed Refactory NHL .</brief_summary>
	<brief_title>Brentuximab Vedotin , Bendamustine , Rituximab Patients With Relapsed Refractory B-cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Complete response ( CR ) rate overall response rate ( ORR ) patient relapse aggressive high-risk non-Hodgkin lymphoma ( NHL ) treat brentuximab vedotin , bendamustine rituximab ( S-BR ) . SECONDARY OBJECTIVES : I . To estimate 2-year progression-free survival ( PFS ) . II . To evaluate rate positron emission tomography ( PET ) -CR correlation 2 year PFS . III . To evaluate toxicity six cycle S-BR . IV . To evaluate mobilization , stem cell collection , engraftment patient proceed salvage autologous stem cell transplant ( ASCT ) . SCIENTIFIC OBJECTIVES : I . To evaluate percentage tumor cell positive negative cluster differentiation ( CD ) 30 immunohistochemistry ( IHC ) , subcellular location CD30 ( membrane cytoplasmic absence membrane expression ) , intensity scoring , correlate clinical outcome . II . To evaluate gene expression profile ( GEP ) Nanostring Technology compare expression level target gene CD30 membrane positive , CD30 cytoplasmic positive CD30 negative tumor cell . III . To evaluate correlation mutation identify next generation sequencing ( NGS ) include ribonucleic acid ( RNA ) sequence tumor transcriptome , correlate GEP CD30 IHC , correlate clinical outcome . IV . To evaluate level soluble CD30 baseline response treatment . SCHEDULE : Patients receive brentuximab vedotin intravenously ( IV ) 30 minute day 1 , bendamustine IV 30-60 minute day 1-2 , rituximab IV day 2 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>CD30 detectable B lineage relapse refractory NHL include follow histology : Aggressive lymphoma : diffuse large B cell lymphoma , primary mediastinal B cell lymphoma , grey zone lymphoma , high grade B cell lymphoma , transform indolent lymphomas Indolent lymphoma : follicular lymphoma , marginal zone lymphoma , small lymphocytic lymphoma ; indolent lymphoma patient eligible trial high tumor burden high risk disease , define : The Groupe d'Etude de Lymphomes Folliculaires ( GELF ) criteria Intermediate high risk Follicular Lymphoma International Prognostic Index ( FLIPI ) score elevate lactose dehydrogenase ( LDH ) / beta2 microglobulin ( B2M ) Subjects 18 75 year old . Subjects old 75 year old discuss PI prior subject consent ; consensus PI treat physician require . Karnofsky performance status ( KPS ) &gt; = 70 % , Eastern Cooperative Oncology Group ( ECOG ) = &lt; 2 At least 1 measurable site disease accord Revised Response Criteria Malignant Lymphoma Patients must receive least one 4 prior line systemic therapy American Heart Association ( AHA ) class 1 without significant limitation physical activity Ejection fraction ( EF ) least &gt; = 40 % multigated acquisition ( MUGA ) echocardiography ( ECHO ) Total bilirubin = &lt; 1.5 mg/dl Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less 2.5 time upper limit normal without evidence active infectious hepatitis Creatinine clearance &gt; = 40 ml/min Platelets &gt; 75,000 cells/ul Absolute neutrophil count ( ANC ) &gt; 1,000 cells/ul Ability provide inform consent Females childbearing potential must negative serum urine betahuman chorionic gonadotropin ( HCG ) pregnancy test screening ; pregnancy test require : ( ) woman postmenopausal least 2 year without menses ; ( b ) woman surgically sterile ( e.g . mean hysterectomy , tubal ligation , etc . ) Males females childbearing potential must able willing use effective contraceptive method treatment three month complete treatment Active infection ( bacterial , fungal , viral ) Evidence sanctuary site involvement disease , e.g. , central nervous system , ocular , testicular involvement Evidence second malignancy , abnormal cytogenetics , morphologic evidence myelodysplastic syndrome ( MDS ) Recent chemotherapy within 3 week screen Major surgery within 4 week screen Diagnosed treated malignancy NHL patient treat , except : malignancy treat curative intent know active disease present &gt; = 3 year subject registration ; adequately treat nonmelanoma skin cancer lentigo maligna without evidence disease ; adequately treat carcinoma situ without evidence disease History stroke intracranial hemorrhage within 6 month prior registration Requires anticoagulation warfarin equivalent vitamin K antagonists Requires treatment strong cytochrome ( CYP3A4/5 ) inhibitor Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , class 3 ( moderate ) class 4 ( severe ) cardiac disease define New York Heart Association Functional Classification Known history human immunodeficiency virus active hepatitis C virus active hepatitis B virus infection uncontrolled active systemic infection require intravenous antibiotic Women pregnant breastfeeding Prior use brentuximab vedotin Prior use bendamustine indolent lymphoma allow &gt; 2 year , CR bendamustine well tolerate residual &gt; grade 1 toxicity ; prior use bendamustine aggressive lymphoma allow Prior allogeneic transplant Patients ChildPugh B C hepatic impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>